Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Vijaya Diagnostic Centre Ltd

| Q4 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤13th May 26

Summary : Vijaya Diagnostic Centre reported strong Q4 FY26 results, driven by network expansion and strategic investments, with bullish outlook for future growth.

Management Perspective positive : Management expressed confidence in achieving future growth, highlighted strong past performance, and emphasized strategic investments in technology and talent. Phrases like 'very successful year,' 'remain confident,' 'strong momentum,' and 'very optimistic' were used.

Concall Report Analysis & Insights

Business Overview

  1. Vijaya Diagnostic Centre delivered 17% revenue CAGR over 5 years, exceeding 15% guidance.
  2. FY26 was a landmark year, with revenues crossing INR 800 crores and 19.5% YoY growth.
  3. Q4 FY26 revenue grew 26.6% YoY to INR 219 crores, driven by 18.5% test volume growth.
  4. EBITDA for Q4 FY26 was INR 95.5 crores, a 38.7% YoY growth, with a 43.5% margin.
  5. The company operates with a B2C-focused integrated business model, with 92% B2C revenue.

Future Growth Prospects

  1. Plans to commission 4-5 hubs and 10-12 spokes across the network in FY27.
  2. Introducing a state-of-the-art automated lab in Panjagutta to enhance productivity.
  3. Planning to introduce advanced Genomic Testing as a specialized diagnostic offering.
  4. Foresees double-digit growth in Hyderabad for the next 2-3 years by adding new spokes.
  5. Confident in double-digit growth for Pune and Bangalore regions in the next 1-2 financial years.

Management Insights

  1. Achieved significant milestones over 5 years, doubling centers and expanding footprint.
  2. Business guided by quality, customer experience, technology investment, and talent development.
  3. FY26 revenue growth was strong across pathology and radiology, supported by seasonality.
  4. New hubs in core markets achieved breakeven faster than guided timelines.
  5. Committed to sustainable financial performance through a disciplined, purpose-driven approach.

Signs of Skepticism

  1. Genomics is a long-term play with no significant revenue expected in the next few years.
  2. Management's margin guidance of 40% is conservative despite current higher margins.
  3. Tracking repeat customers is still in early stages, needing 2-3 more years for clear data.
  4. No immediate plans to explore a franchise model, limiting potential expansion avenues.

Risk Factors

  1. Genomics is a long-term play, not expected to generate significant revenue in the near future.
  2. Competition is significant in the genomics space, which is a smaller market currently.
  3. Corporate segment experiences churn due to price-sensitive aggregators and competition.
  4. New center ramp-up can be dynamic across geographies, impacting short-term growth.

Good To Know

  1. Capital expenditure outlay for FY26 was INR 169 crores, including replacement capex.
  2. Estimated capex for FY27 is INR 140-150 crores for new centers and automated lab.
  3. The company has a cash balance of INR 280-300 crores, with plans for potential inorganic expansion.
  4. Wellness segment shows consistent 30% growth, with packages mixing radiology and pathology.
  5. Price hike of 1-1.5% is planned for FY27, following a Q1 FY26 hike.

Key Drivers

  1. Strong Q4 FY26 revenue and EBITDA growth.
  2. Aggressive network expansion with new hubs.
  3. Investment in advanced automated lab technology.
  4. Introduction of specialized Genomic Testing.

Key Analyst Discussions

Competitive Environment

  1. Competition from hospital-based labs is managed by offering integrated services and affordability.
  2. Online players have minimal impact as they often outsource diagnostics to established players.
  3. Differentiated service includes large format centers and competitive pricing (20-25% cheaper than hospitals).
  4. Bangalore market has multiple small integrated players, creating opportunity for Vijaya.

Market Trends & Consumer Behavior

  1. Wellness segment shows consistent 30% growth, driven by both corporate and retail demand.
  2. No significant traction observed from recent weight loss drugs going generic.
  3. Hyderabad market, though mature, is still growing at 20% due to quality and service offerings.
  4. Customer experience and affordability are key pillars for attracting and retaining customers.

Financial Highlights

  1. EBITDA margin outperformance driven by operating leverage and faster new center breakeven.
  2. Revenue per test increased due to new hubs ramping up, especially in radiology.
  3. Pre-Ind AS margin for FY26 is estimated to be around 35% for the entire year.
  4. Maintenance capex for FY27 is projected to be INR 10-15 crores.
  5. Company plans 1-1.5% price hike in FY27, similar to Q1 FY26.

Product Composition

  1. Wellness packages typically have a 50-50 mix of radiology and pathology tests.
  2. New hubs initially driven by radiology, influencing revenue per test.
  3. Genomic testing is a specialized offering, planned for gradual growth through B2C walk-ins.
  4. Company focuses on volume-driven growth and capacity addition for the next 2-3 years.

Strategic Considerations

  1. No plans for new geographic clusters in North India for the next 3-5 years.
  2. Focus on building denser networks in existing and newly acquired states (Karnataka, West Bengal, Pune).
  3. Inorganic expansion considered if assets align with B2C-driven value system and ethos.
  4. Investment in CRM, ERP, and AI solutions is ongoing, with launches in current financial year.
  5. No current plans to explore a franchise model; all centers are company-owned and operated.